The plan, based on stakeholder input, shares FDA's intended actions to support regulation of artificial intelligence and machine learning.

If your email program has trouble displaying this email, view as a webpage. The FDA issues Artificial Intelligence and Machine Learning (AI/ML) Software as a Medical Device Action Plan Today, the U.S. Food and Drug Administration (FDA) issued the "Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan" from the Center for Devices and Radiological Health's Digital Health Center of Excellence. The Action Plan is a direct response to stakeholder feedback to the April 2019 discussion paper, "Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device" and outlines five actions the FDA intends to take, which include: Further developing the proposed regulatory framework, including issuing draft guidance on a predetermined change control plan; Supporting the development of good machine learning practices to evaluate and improve machine learning algorithms; Fostering a patient-centered approach, including device transparency to users; Developing methods to evaluate and improve machine learning algorithms; and Advancing real-world performance monitoring pilots. AI/ML-based SaMD is a rapidly progressing field and the FDA anticipates this action plan will continue to evolve. The FDA welcomes continued feedback in this area and looks forward to engaging with stakeholders on these efforts. We will also continue to collaborate across the FDA to build a coordinated approach in areas of common focus related to AI/ML. Read the Action Plan About the Digital Health Center of Excellence Launched in September 2020 and located in the Center for Devices and Radiological Health (CDRH), the Digital Health Center of Excellence is committed to strategically advance science and evidence for digital health technologies within the framework of the FDA's regulatory and oversight role. The goal of the Digital Health Center of Excellence is to empower stakeholders to advance health care by fostering responsible and high-quality digital health innovation. Questions? If you have questions about the Digital Health Center of Excellence, email digitalhealth@fda.hhs.gov.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA